Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC

Summary

The goal of this clinical trial is to evaluate the clinical efficacy and safety of Furmonertinib in EGFR mutated NSCLC patients with leptomeningeal metastasis and to explore the feasibility of CSF ctDNA detection for efficacy evaluation. Participants will be treated with 160mg Furmonertinib daily and tumor evaluation will be performed every 6-8 weeks. The participants' blood and cerebrospinal fluid samples will be collected three times during the study for ctDNA detection.

Timeline

Start

2022-04-15

Primary completion

2025-04-30

Completion

2025-08-31

Drugs

Indications